Nasdaq Moves to Delist PRF Technologies After Sub-$1 Bid; Hearing Request Stays Suspension
PRFX sits 23% above its 52-week low of $0.641 on light trading volume (0.2× avg).
Summary
Nasdaq's Listing Qualifications staff issued a delisting determination on November 9 after PRFX's closing bid stayed below $1.00 for 30 straight business days, from September 24 through November 4, 2026. The company gets no standard 180-day cure period because it already ran a 1-for-5 reverse split on February 6, 2026, inside the prior year. PRFX filed a timely hearing request before the November 16 deadline, which keeps the shares trading on the Nasdaq Capital Market under PRFX while the Panel decides. Management says it will pitch a compliance plan that may include another reverse split; the Panel can grant up to 180 days, or until May 8, 2027. The notice lands on top of an activist fight — S.H.N. Financial Investments petitioned a Tel Aviv court on November 2 to force a special meeting to replace most of the board — and a non-binding term sheet to sell the GridFeed/DeepSolar platform to Dotz. Interim CEO Efraim Cohen-Arazi cited roughly $11.0 million in cash and short-term deposits at September 30, 2026, and said LayerBio expects to start Phase 2 enrollment for OcuRing-K before year-end 2026. A delisting would hit liquidity and the company's ability to raise capital, and the stock already trades far below the $1 threshold.
At the time of this announcement, PRFX was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.64 to $7.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.